Payment overview · 2025
General Payments
$1,144.28
45 reported records · 17 companies
Healthcare provider profile · identity verified
Allen L Beachy, MD
Allopathic & Osteopathic Physicians|Family Medicine · FORT SMITH, AR · NPI 1104853860
Verified facts
What the public records show
CMS Open Payments records show Allen L Beachy, MD received $1,144.28 in general payments during 2025 across 45 reported records.
Novo Nordisk Inc accounted for 17.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 28 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 148 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $201.77 | 17.6% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $176.63 | 15.4% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $166.37 | 14.5% | 13 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $143.50 | 12.5% | 6 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $124.97 | 10.9% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $70.04 | 6.1% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $52.64 | 4.6% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $32.21 | 2.8% | 2 | 2025 |
| Pharming Healthcare, Inc. | Unresolved — no canonical attribution shown | $27.43 | 2.4% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $26.47 | 2.3% | 1 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $22.96 | 2.0% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $19.75 | 1.7% | 1 | 2025 |
| BETA BIONICS, INC. | Unresolved — no canonical attribution shown | $19.43 | 1.7% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.18 | 1.5% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $15.79 | 1.4% | 1 | 2025 |
| Dynavax Technologies Corporation | Unresolved — no canonical attribution shown | $13.64 | 1.2% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $13.50 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,144.28 | 45 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $184.17 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $126.89 | 5 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $124.97 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $124.97 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $97.84 | 8 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $70.04 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $68.70 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $68.53 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $68.53 | 5 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $52.64 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $52.09 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $51.66 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $51.66 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $51.66 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $42.59 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $32.21 | 2 | 2025 |
Source payment records
|
|||||
| RUCONEST Normalized: ruconest |
Biological | Pharming Healthcare, Inc. | $27.43 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $26.47 | 1 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $22.96 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $19.75 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $19.75 | 1 | 2025 |
Source payment records
|
|||||
| iLet Bionic Pancreas Normalized: ilet bionic pancreas |
Device | BETA BIONICS, INC. | $19.43 | 1 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Contact Detach Normalized: ilet insulin infusion kit contact detach |
Device | BETA BIONICS, INC. | $19.43 | 1 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Inset Normalized: ilet insulin infusion kit inset |
Device | BETA BIONICS, INC. | $19.43 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $17.18 | 1 | 2025 |
Source payment records
|
|||||
| VIBERZI Normalized: viberzi |
Drug | ABBVIE INC. | $15.79 | 1 | 2025 |
Source payment records
|
|||||
| Heplisav-B Normalized: heplisav b |
Drug | Dynavax Technologies Corporation | $13.64 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $13.50 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 89 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 85 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 62 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 116 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
89 | 20 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
85 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
85 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
62 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
116 | 26 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
148 | 26 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 577 | 150 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 573 | 153 |
| Amlodipine Besylate | Amlodipine Besylate | 460 | 125 |
| Levothyroxine Sodium | Levothyroxine Sodium | 395 | 95 |
| Metoprolol Succinate | Metoprolol Succinate | 327 | 86 |
| Pravastatin Sodium | Pravastatin Sodium | 318 | 84 |
| Irbesartan | Irbesartan | 280 | 75 |
| Tamsulosin Hcl | Tamsulosin Hcl | 263 | 72 |
| Omeprazole | Omeprazole | 252 | 66 |
| Gabapentin | Gabapentin | 231 | 64 |
| Pantoprazole Sodium | Pantoprazole Sodium | 231 | 59 |
| Trazodone Hcl | Trazodone Hcl | 226 | 45 |
| Escitalopram Oxalate | Escitalopram Oxalate | 207 | 53 |
| Tramadol Hcl | Tramadol Hcl | 205 | 47 |
| Finasteride | Finasteride | 200 | 49 |
| Metformin Hcl Er | Metformin Hcl | 198 | 52 |
| Metformin Hcl | Metformin Hcl | 197 | 50 |
| Meloxicam | Meloxicam | 195 | 55 |
| Potassium Chloride | Potassium Chloride | 194 | 49 |
| Losartan Potassium | Losartan Potassium | 190 | 57 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 171 | 31 |
| Fluoxetine Hcl | Fluoxetine Hcl | 158 | 35 |
| Allopurinol | Allopurinol | 156 | 42 |
| Lisinopril | Lisinopril | 153 | 45 |
| Eliquis | Apixaban | 148 | 26 |
| Hydrochlorothiazide | Hydrochlorothiazide | 138 | 40 |
| Benazepril Hcl | Benazepril Hcl | 136 | 40 |
| Carvedilol | Carvedilol | 135 | 35 |
| Furosemide | Furosemide | 123 | 32 |
| Zolpidem Tartrate | Zolpidem Tartrate | 123 | 24 |
| Valsartan | Valsartan | 119 | 32 |
| Ozempic | Semaglutide | 116 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 115 | 31 |
| Clonazepam | Clonazepam | 112 | 18 |
| Ezetimibe | Ezetimibe | 107 | 31 |
| Metoprolol Tartrate | Metoprolol Tartrate | 104 | 28 |
| Simvastatin | Simvastatin | 102 | 28 |
| Alendronate Sodium | Alendronate Sodium | 101 | 23 |
| Spironolactone | Spironolactone | 98 | 30 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 97 | 24 |
| Alprazolam | Alprazolam | 90 | 23 |
| Buspirone Hcl | Buspirone Hcl | 90 | 18 |
| Farxiga | Dapagliflozin Propanediol | 89 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 86 | 22 |
| Jardiance | Empagliflozin | 85 | 20 |
| Famotidine | Famotidine | 79 | 26 |
| Bupropion Xl | Bupropion Hcl | 78 | 23 |
| Celecoxib | Celecoxib | 78 | 17 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 77 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 74 | 22 |
| Pioglitazone Hcl | Pioglitazone Hcl | 74 | 17 |
| Doxazosin Mesylate | Doxazosin Mesylate | 71 | 18 |
| Tizanidine Hcl | Tizanidine Hcl | 70 | 19 |
| Lorazepam | Lorazepam | 69 | 15 |
| Warfarin Sodium | Warfarin Sodium | 69 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 66 | 23 |
| Mounjaro | Tirzepatide | 62 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 61 | 21 |
| Doxepin Hcl | Doxepin Hcl | 60 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 58 | 14 |
| Memantine Hcl | Memantine Hcl | 56 | 13 |
| Montelukast Sodium | Montelukast Sodium | 56 | 12 |
| Mupirocin | Mupirocin | 56 | 22 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 54 | 12 |
| Sertraline Hcl | Sertraline Hcl | 52 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 51 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 48 | 11 |
| Pregabalin | Pregabalin | 48 | 15 |
| Azithromycin | Azithromycin | 47 | 42 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 47 | 27 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 46 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 46 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 45 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 43 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 43 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 40 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 40 | suppressed |
| Aripiprazole | Aripiprazole | 39 | suppressed |
| Lovastatin | Lovastatin | 39 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 39 | 14 |
| Fenofibrate | Fenofibrate | 34 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 34 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 33 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 31 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 30 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 28 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 28 | 13 |
| Bupropion Hcl Sr | Bupropion Hcl | 27 | suppressed |
| Dutasteride | Dutasteride | 27 | suppressed |
| Ketoconazole | Ketoconazole | 27 | 15 |
| Ondansetron Odt | Ondansetron | 27 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 27 | suppressed |
| Trulicity | Dulaglutide | 27 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 26 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 26 | suppressed |
| Temazepam | Temazepam | 26 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 26 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 25 | suppressed |
| Eszopiclone | Eszopiclone | 25 | suppressed |
| Fluconazole | Fluconazole | 25 | 18 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 25 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 25 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 24 | suppressed |
| Xarelto | Rivaroxaban | 23 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 22 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 22 | suppressed |
| Methocarbamol | Methocarbamol | 22 | suppressed |
| Prednisone | Prednisone | 21 | 16 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 21 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 20 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 20 | 15 |
| Diazepam | Diazepam | 20 | suppressed |
| Levetiracetam | Levetiracetam | 20 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Repaglinide | Repaglinide | 20 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 20 | suppressed |
| Amoxicillin | Amoxicillin | 19 | 15 |
| Breo Ellipta | Fluticasone/Vilanterol | 19 | suppressed |
| Galantamine Er | Galantamine Hbr | 19 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 19 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Primidone | Primidone | 19 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 19 | suppressed |
| Sulindac | Sulindac | 19 | suppressed |
| Telmisartan | Telmisartan | 19 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 18 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 18 | suppressed |
| Naproxen | Naproxen | 18 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 18 | suppressed |
| Ramipril | Ramipril | 18 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Estradiol | Estradiol | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Belsomra | Suvorexant | 15 | suppressed |
| Invokana | Canagliflozin | 15 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 15 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 14 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 14 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 12 | 12 |
| Colestipol Hcl | Colestipol Hcl | 12 | suppressed |
| Mirtazapine | Mirtazapine | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 12 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Testosterone | Testosterone | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 11 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,144.28 · 45 records | Novo Nordisk Inc | ABRYSVO, AIRSUPRA, BREZTRI, COMIRNATY, Cologuard Collection Kit, EVENITY, FARXIGA, GEMTESA, Heplisav-B, JARDIANCE, Kerendia, LEQVIO, Leqembi, MOUNJARO, OTEZLA, Ozempic, PREVNAR 20, QUTENZA, REPATHA, REXULTI, RUCONEST, Rybelsus, VIBERZI, ZAVZPRET, ZEPBOUND, iLet Bionic Pancreas, iLet Insulin Infusion Kit Contact Detach, iLet Insulin Infusion Kit Inset | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error